Oral GLP‑1 Foundayo OK'd
The FDA has approved Eli Lilly’s oral GLP‑1 pill Foundayo (orforglipron), which immediately puts an oral competitor into the weight‑loss market and shifts how patients and clinicians might choose therapies. (The approval was reported alongside industry coverage noting the new pill’s market implications.) (Managed Healthcare Executive) ((biospace.com))
Your gut already makes a hormone that tells your brain you’ve eaten enough. Eli Lilly just got United States approval for a pill that copies that signal, so a treatment that usually comes as a weekly shot can now come as a once-daily tablet called Foundayo, with the generic name orforglipron. (fda.gov) That hormone is called glucagon-like peptide-1, and drugmakers have spent years turning it into medicines that slow stomach emptying and cut appetite. The catch is that most of the best-known weight-loss versions, including injectable semaglutide sold as Wegovy, require needles. (nejm.org) Making this kind of drug into a pill has been unusually hard because peptide drugs are fragile, like trying to mail ice sculpture through summer heat. Orforglipron is a small-molecule drug rather than a peptide, which is why Lilly says it can be taken any time of day without food or water restrictions. (drugs.com) (medical.lilly.com) The Food and Drug Administration approved Foundayo on April 1, 2026, for chronic weight management in adults with obesity, and in some adults with overweight plus at least one weight-related condition. The agency also said the decision came 50 days after filing and 294 days before the original Prescription Drug User Fee Act target date of January 20, 2027. (fda.gov) (foundayo.lilly.com) The approval rests on a phase 3 study that followed adults with obesity for 72 weeks. In that trial, average weight change was minus 7.5 percent with 6 milligrams, minus 8.4 percent with 12 milligrams, and minus 11.2 percent with 36 milligrams, versus minus 2.1 percent with placebo. (nejm.org) The side effects looked familiar to anyone who has followed this drug class. The most common problems were stomach-related, and treatment discontinuation ranged from 5.3 percent to 10.3 percent on orforglipron versus 2.7 percent on placebo in the same study. (nejm.org) The label carries the same kind of thyroid tumor warning seen across glucagon-like peptide-1 drugs, and it says the medicine should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. The prescribing information also lists nausea, diarrhea, vomiting, constipation, indigestion, and stomach pain among common adverse reactions. (drugs.com) This changes the market because doctors and patients are no longer choosing only between “effective shot” and “less effective older pill.” They now have a branded obesity pill in the same broad drug family as the blockbuster injectables, but with no needle and no fasting instructions. (medical.lilly.com) (managedhealthcareexecutive.com) That convenience could matter as much as the biology for some patients, because weekly injections can be a barrier even when insurance covers them. A daily tablet also fits more easily into the way primary-care doctors already prescribe blood-pressure, cholesterol, and diabetes medicines. (managedhealthcareexecutive.com) (foundayo.lilly.com) Lilly is also running a much larger race than weight loss alone. The company has already said it is studying orforglipron in type 2 diabetes and obstructive sleep apnea, which means this pill could end up competing across several of the same categories that turned injectable glucagon-like peptide-1 drugs into one of the biggest pharmaceutical markets in years. (medical.lilly.com)
